An 18-month congressional investigation found the Food and Drug Administration didn't follow its own guidance and inappropriately collaborated with drugmaker Biogen before the approval of a controversial Alzheimer's drug last year.
Why it matters: The findings, released in a report Thursday by the House Oversight and Energy and Commerce committees, come as the FDA reviews two other Alzheimer's drugs that target proteins believed to contribute to the development of Alzheimer's.
